LNWTC
INMB icon

Laird Norton Wetherby Trust Company’s INmune Bio INMB Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$113K – 89
2023
Q4 		$113K Buy
+10,000
New +$83.8K 0.01% 76

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laird Norton Wetherby Trust Company's INMB Position: Q1 2026 in Review

Laird Norton Wetherby Trust Company increased its INmune Bio (INMB) stake by 11% in Q1 2026, buying an estimated $7.13K and bringing the position to 50,000 shares worth $56.5K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Laird Norton Wetherby Trust Company first reported a position in INMB in Q4 2023 and has held it in 10 quarters since. The position peaked at $370K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Laird Norton Wetherby Trust Company held 50,000 shares of INmune Bio worth $56.5K as of Q1 2026.
  • Laird Norton Wetherby Trust Company bought 5,000 INmune Bio shares in Q1 2026, an estimated $7.13K.
  • INmune Bio made up ﹤0.01% of Laird Norton Wetherby Trust Company's portfolio in Q1 2026, its #980 holding.
  • Laird Norton Wetherby Trust Company first reported a position in INmune Bio in Q4 2023 and has held it in 10 quarters since.
  • Laird Norton Wetherby Trust Company's INmune Bio position peaked at $370K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q1 2026, filed 15 May 2026.